Last reviewed · How we verify
NCT03658837
Gastrointestinal Functional Outcome Ivor Lewis
trial testing Ivor Lewis Oesophagectomy in Oesophageal Cancer in 75 participants. Completed in 1 December 2019.
1 December 2019
Quick facts
| Lead sponsor | University Hospitals, Leicester |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 3 January 2019 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 December 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Ivor Lewis Oesophagectomy
Conditions studied
- Oesophageal Cancer — all drugs for Oesophageal Cancer →
Sponsor
University Hospitals, Leicester
Who can join
18 and older, any sex, with Oesophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study focuses on the prevalence of functional complications and their impact on QOL in patients who underwent an Ivor Lewis Oesophagectomy. This study will assess the prevalence of gastrointestinal symptoms and QOL from beyond the first year following surgery up to 5 years. The aim is to determine whether gastrointestinal side effects and QOL are compromised in the long-term. This study will also explore in details, the impact of surgery on their quality of life and gastro intestinal symptoms that patients has experienced post operatively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03658837
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oesophageal Cancer
Currently open trials in the same condition.
- NCT06906887 — PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer · Phase 2 · recruiting
- NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
- NCT06364553 — Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study · NA · recruiting
- NCT06440174 — Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients with Oesophageal Cancer (VALUE) · recruiting
- NCT06212700 — PRIORITY-CONNECT 2 Pilot Trial · NA · recruiting
Other University Hospitals, Leicester trials
Trials by the same sponsor.
- NCT06179771 — Pilot Study on HA380 Column Use in Critically Ill Patients Receiving Extracorporeal Support. · NA · recruiting
- NCT06269172 — Perceptions Across Ethnicities to Develop an Adapted Intervention for Breathlessness · unknown
- NCT06152406 — Ablate and Pace HIS Study · NA · recruiting
- NCT06523192 — Validation of the English Version of the Drug Hypersensitivity Quality of Life Questionnaire · completed
- NCT06025422 — In-shoe Pressures Associated With Footwear Fit Guidelines · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03658837 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals, Leicester
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03658837.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing